For US Patients Only

KENALOG Spray Reduces Redness and Swelling3

With a cooling and soothing effect on your skin3

The propellant in KENALOG Spray is proven to immediately cool your skin and temporarily interrupt pain.3

These before and after photographs show you how KENALOG Spray has helped people with different skin conditions.

Please see the bottom of this page for full Prescribing Information.

 

KENALOG Spray: Results You Can See

Lichen Simplex Chronicus (Elbow)
A female patient was diagnosed with lichen simplex chronicus of the elbow, which caused severe itching and redness. The patient was clear from all signs and symptoms of lichen simplex chronicus in 1 week. KENALOG Spray was applied twice daily for 7 days.

kenalog-elbow-before kenalog-elbow-after

Photographs courtesy of Stephan Mahoney, MD.

 

Acute Contact Dermatitis, Poison Ivy (Ankle)
Male patient diagnosed with acute contact dermatitis from poison ivy. Patient came into contact with poison ivy while gardening. Patient was clear from all signs and symptoms of contact dermatitis in 2 weeks. KENALOG Spray was applied twice daily for 2 weeks.

kenalog-ankle-before kenalog-ankle-after

Photographs courtesy of Stephan Mahoney, MD.

 

Contact Dermatitis (Neck)
Male patient diagnosed with contact dermatitis. Patient complained about severe itching, redness, and pain. Patient’s condition improved after 7 days of treatment with KENALOG Spray. KENALOG Spray was applied twice daily for 7 days.

kenalog-neck-before kenalog-neck-after

Photographs courtesy of Stephan Mahoney, MD.

 

Psoriasis (Leg)
Improvement in male patient diagnosed with leg psoriasis. Photographs were taken at baseline, after using KENALOG Spray twice daily for 7 days, and after using KENALOG Spray twice daily for 3 weeks.

kenalog-leg-baseline kenalog-leg-day7 kenalog-leg-day21

Photographs courtesy of Joseph Fowler, MD.

 

Psoriasis (Scalp)
Improvement in male patient diagnosed with scalp psoriasis. Photographs were taken at baseline and after using KENALOG Spray twice daily for 7 days.

kenalog-head-before kenalog-head-after

Photographs courtesy of Joseph Fowler, MD.

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE: KENALOG Spray (Triamcinolone Acetonide Topical Aerosol, USP) is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

SUMMARY OF RISK INFORMATION FOR KENALOG SPRAY

CONTRAINDICATIONS: Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

PRECAUTIONS: Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface area, prolonged use, and the addition of occlusive dressings.

Patients receiving a large dose of any topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio.

Caution should be exercised when topical corticosteroids are administered to a nursing woman.

This preparation is not for ophthalmic, oral, or intravaginal use.
For topical use only. Please see Full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Reference: 3. Linkner RV, Sohn AS, Goldberg K, Lebwohl M. Assessment of the cooling effect of triamcinolone acetonide aerosol when used for steroid-responsive dermatoses. Poster presented at: Mount Sinai School of Medicine; New York, NY.
KENALOG is a licensed trademark of Bristol-Myers Squibb Company. All other trademarks are property of their respective owners.

Important Safety Information

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE: KENALOG Spray (Triamcinolone Acetonide Topical Aerosol, USP) is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

SUMMARY OF RISK INFORMATION FOR KENALOG SPRAY

CONTRAINDICATIONS: Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

PRECAUTIONS: Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface area, prolonged use, and the addition of occlusive dressings.

Patients receiving a large dose of any topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio.

Caution should be exercised when topical corticosteroids are administered to a nursing woman.

This preparation is not for ophthalmic, oral, or intravaginal use.
For topical use only. Please see Full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.